Advancell Pty Ltd

Based in New South Wales, Australia, and founded in 2019, Advancell Isotopes Pty Ltd operates as a radiopharmaceutical company that develops and produces cancer drugs. The company was founded by its CEO Andrew Adamovich. In February 2025, Advancell Pty Ltd raised USD 112 million in series C funding co-led by new investors SV Health Investors, Symbiosis Capital Management, Abingworth, and Sanofi Ventures, with participation from other new investors Tenmile and Brandon Capital Partners. Returning investor Morningside Group, 5Y Capital and other unspecified investors also participated in the round.

AdvanCell’s product line includes Alpha 212®, which is a drug that is produced with the help of targeted alpha therapy technology that is used for the treatment of cancer; ²¹²Pb, which is an alpha isotope generator platform that develops therapeutic pipeline clinical programs including ADVC001 (prostate cancer), ADVC001 (melanoma), ADVC003 (pancreatic cancer and breast cancer); and The AdvanCell ²¹²Pb Generator, which is a technology that produces alpha radioligand treatments. The company will use the February 2025 funding to expand its manufacturing capacity, accelerate the clinical development of its radionuclide therapies, and support its ongoing trials for ADVC001 in metastatic prostate cancer.